Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Jul 7, 2015; 21(25): 7860-7868
Published online Jul 7, 2015. doi: 10.3748/wjg.v21.i25.7860
Figure 1
Figure 1 Presentation of the baseline and repeat liver biopsies in 3 metabolic syndrome patients with non-alcoholic steatohepatitis on rosuvastatin (10 mg/d) monotherapy for 12 mo. On the left panel liver biopsies of patients with non-alcoholic steatohepatitis presenting steatosis (fat content of the liver > 30%), hepatocyte ballooning degeneration, diffuse lobular mixed acute and chronic inflammation, and perivenular, perisinusoidal collagen disposition. On the right panel liver biopsies of the same 3 patients after one year monotherapy with 10 mg/d of rosuvastatin presenting total normal liver tissue.